The Challenge: Traditional Cell Therapy Manufacturing Limitations

The therapeutic promise of cell therapies, such as CAR-T cell therapies for cancer and other conditions, has been hampered by significant manufacturing challenges. Traditional methods are predominantly manual, labor-intensive, and operate at a small scale. This results in:

• High Costs: Manual processes and extensive cleanroom requirements drive up the per-dose cost, limiting patient access.
• Scalability Issues: Difficulty in scaling out (producing more doses) and scaling up (increasing batch size) to meet clinical and commercial demand.
• Process Variability & Failure Rates: Manual handling increases the risk of errors, contamination, and process failures, leading to lost batches and delays.
• Long Turnaround Times: Complex logistics and lengthy manufacturing processes impact the speed at which therapies can be delivered to patients.
• Skilled Labor Dependency: Heavy reliance on highly trained personnel, which can be a scarce resource.

Cellares was founded to address these critical limitations by leveraging advanced automation, robotics, and software to industrialize cell therapy manufacturing.

Cellares' Solution: The Cell Shuttle? and Cell Q? Platforms

At the heart of Cellares' offering are its proprietary, automated platforms:

1. The Cell Shuttle? - Automated Cell Therapy Manufacturing Platform: The Cell Shuttle is a self-contained, automated "factory-in-a-box" designed for end-to-end manufacturing of cell therapies. Key features and capabilities include:

• True Walk-Away Automation: Integrates and automates all critical unit operations of cell therapy manufacturing, including cell isolation/enrichment, selection, gene modification (e.g., viral transduction or non-viral electroporation), activation, expansion, washing/concentration, and final formulation.
• High Throughput and Parallel Processing: A single Cell Shuttle can process multiple (e.g., 10+ or even up to 16) patient batches simultaneously and independently, enabling significant scale compared to manual methods.
• Closed System and Single-Use Consumables: Utilizes pre-sterilized, single-use, disposable cartridges and reagent kits for each batch. This closed-system approach minimizes the risk of cross-contamination and human error, and simplifies changeover between different products.
• Flexibility and Software-Defined Manufacturing (SDM): The platform is designed to be adaptable to a wide range of cell therapy modalities (autologous and allogeneic) and processes. Specific manufacturing protocols are defined by software, allowing for rapid process changes and tech transfer between Cell Shuttles.
• GMP Compliance: Designed and built to meet Current Good Manufacturing Practice (cGMP) requirements, crucial for producing clinical and commercial-grade therapies. The Cell Shuttle has received FDA Advanced Manufacturing Technology (AMT) designation, which can expedite regulatory reviews for clients using the platform.
• Reduced Footprint and Labor: Significantly reduces the need for large, complex cleanroom facilities and the amount of manual labor required per batch.
• Integrated In-Process Monitoring: Incorporates sensors and analytics for real-time monitoring and control of critical process parameters.

2. The Cell Q? - Automated Quality Control (QC) Workcell: Complementing the Cell Shuttle, Cellares developed Cell Q?, an automated workcell designed to address bottlenecks in cell therapy quality control. * Automated QC Testing: Automates a wide array of common in-process and final product release assays required for cell therapies. * High Throughput: Capable of handling QC testing for thousands of cell therapy batches per year. * Integration with Cell Shuttle: Designed to work seamlessly within the Cellares IDMO ecosystem. * Pre-qualified Assays: Includes a set of pre-qualified assays to accelerate analytical method transfer for new clients. * Modularity: Can be expanded to incorporate new analytical instruments as needed.

The Integrated Development and Manufacturing Organization (IDMO) Model

Cellares is pioneering the IDMO model, moving beyond being just a technology provider to offering comprehensive manufacturing services. This model involves:

• IDMO Smart Factories: Cellares is establishing a global network of cGMP-compliant "Smart Factories" equipped with multiple Cell Shuttles and Cell Q platforms. These facilities provide the infrastructure for scalable cell therapy production.
• End-to-End Services: The IDMO model offers a suite of services to cell therapy developers:
  • Technology Adoption Program (TAP): A program designed for therapy developers to evaluate and adapt their specific cell therapy processes for automation on the Cell Shuttle platform. This typically involves process mapping, feasibility studies, and pilot runs.
  • Process and Analytical Development: Optimizing existing manual processes for automation, developing new automated processes, and establishing robust analytical methods.
  • Clinical and Commercial cGMP Manufacturing: Manufacturing cell therapy products for all phases of clinical trials and for commercial supply. Cellares offers flexible capacity reservation models, including shared, hybrid, and dedicated Cell Shuttle deployments.
  • Regulatory Support: Providing expertise and documentation to support CMC (Chemistry, Manufacturing, and Controls) sections of regulatory filings (e.g., INDs, BLAs).
  • Quality Assurance and Quality Control: Implementing comprehensive quality systems to ensure product safety, efficacy, and consistency.
  • Globalization Package: Facilitating rapid tech transfer and manufacturing scale-out across its global network of Smart Factories.

Products and Services Offered

Cellares' offerings can be summarized as:

• Products:

  • The Cell Shuttle?: The core automated cell therapy manufacturing platform.
  • The Cell Q?: The automated QC workcell.
  • Proprietary Consumables: Single-use, sterile cartridges and reagent kits specifically designed for the Cell Shuttle.
  • Software Suite: Integrated software for process design, execution (Software-Defined Manufacturing), monitoring, data management, and electronic batch records (EBRs), compliant with 21 CFR Part 11.

• Services (via the IDMO model):

  • Process Transfer and Automation: Migrating manual processes to the Cell Shuttle.
  • Process Optimization and Development.
  • Analytical Method Development and Qualification.
  • cGMP Manufacturing for Clinical Trials (Phase I, II, III).
  • Commercial-Scale cGMP Manufacturing.
  • Quality Control and Release Testing.
  • Regulatory Affairs Support (CMC focus).
  • Supply Chain and Logistics Management within the Smart Factory ecosystem.

Benefits and Impact on Cell Therapy

The Cellares approach aims to deliver significant benefits to the cell therapy field:

• Increased Scalability: Enabling the production of tens of thousands of patient doses per year from a single facility.
• Reduced Manufacturing Costs: Automation and reduced labor/facility requirements can lower the per-batch cost by up to 50-75% compared to conventional methods.
• Lower Process Failure Rates: Closed systems and automation minimize manual errors and contamination risks, potentially reducing manufacturing failures by up to 75%.
• Faster Turnaround Times & Tech Transfer: Software-defined manufacturing and standardized platforms can accelerate process development, tech transfer between sites, and overall production timelines.
• Improved Product Quality and Consistency: Automation leads to more reproducible and consistent manufacturing processes.
• Democratized Access: By making cell therapy manufacturing more efficient and affordable, Cellares aims to enable broader patient access to these life-saving treatments.
• Support for Diverse Modalities: The platform's flexibility is intended to support various cell types and gene editing technologies (e.g., CAR-T, TCR, NK cells, Tregs, HSCs, iPSCs, CRISPR-edited therapies).

Collaborations and Market Position

Cellares has established significant partnerships with leading pharmaceutical companies and academic institutions to validate and implement its technology. Notable collaborations include agreements with Bristol Myers Squibb (a major capacity reservation and supply agreement for CAR-T therapies), Kite (a Gilead Company), Cabaletta Bio, Lyell Immunopharma, and the University of Wisconsin. These partnerships underscore the industry's interest in Cellares' automated manufacturing solutions.

With substantial funding and a clear vision, Cellares is positioning itself as a transformative force in cell therapy manufacturing, aiming to become the de facto standard for producing these complex therapies at a global scale.